Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0991, caspofungin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0991, caspofungin acetate | DRUG | - |
| Comparator: amphotericin B | DRUG | - |
| Comparator: lipid formulation of amphotericin B and/or azole | DRUG | - |
* Patients must meet a specific definition of probable or definite invasive aspergillosis and be considered to have failed or be intolerant of standard antifungal therapy. * The patient must be at least 16 years old and if a woman of childbearing potential, must have a negative serum or urine pregna...
MK0991 is an investigational small molecule being studied for the treatment of aspergillosis, a fungal infection. It is currently in Phase 2 clinical development and has been evaluated in combination with standard antifungal agents for salvage therapy of invasive aspergillosis.
MK0991 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with aspergillosis.
MK0991 is in Phase 2 clinical development for aspergillosis. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical evaluation to determine its safety and effectiveness.
MK0991 has been studied in a completed Phase 2 clinical trial with the identifier NCT00076869. This trial evaluated MK0991 in combination with standard antifungal agents for the treatment of salvage invasive aspergillosis and enrolled 55 participants aged 16 years and older.
Yes, MK0991 is also known as caspofungin. Both names refer to the same investigational drug being developed by Merck & Company, Inc. for the treatment of aspergillosis. The drug is currently in Phase 2 clinical trials.